Cancer MoonShot 2020 Announces the Formation of a National Pediatrics Consortium, a Major Milestone in the War on Cancer in Children

Leading national children’s hospitals, pediatric cancer organizations
and academic centers unite with Cancer MoonShot 2020 to accelerate
bringing the next-generation standard of cancer care and immunotherapy
to children with cancer

The Cancer MoonShot 2020 Pediatrics Consortium include 10 founding
members spanning major cities across the nation who will participate in
a national data sharing infrastructure to accelerate clinical
development of next-generation immunotherapy

PHOENIX–(BUSINESS WIRE)–In a press conference today, Cancer MoonShot 2020 announced another
milestone in its quest to alter the course of cancer care with the
formation of the Pediatrics Consortium focused on bringing the promise
of combined immunotherapy as the next-generation standard of cancer care
to children diagnosed with the disease. With leadership at
Phoenix Children’s Hospital helping to initiate this consortium, all
founding partners will seek to apply the most comprehensive cancer
molecular diagnostic testing available—integrating whole genomic and
proteomic analysis—and leverage proven and promising combination
immunotherapies and clinical trials through the QUILT (QUantitative Integrative Lifelong Trial)
Program within the Cancer MoonShot 2020 mission. Real time data sharing,
enabled by the infrastructure provided by Cancer MoonShot 2020, will
accelerate clinical learning and insight to all members participating in
the consortium.

Founding Members in the Cancer MoonShot 2020 Pediatrics Consortium

  1.   Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago IL
2. Children’s Healthcare of Atlanta, GA, Aflac Cancer & Blood Disorders
3. Children’s Hospital of Orange County, CA
4. Children’s Hospital of Philadelphia, PA
5. Children’s Hospital of Pittsburgh of UPMC, PA
6. Duke Department of Pediatrics – Duke University School of Medicine,
7. Floating Hospital for Children at Tufts Medical Center, MA

Huntsman Cancer Institute at the University of Utah and
Intermountain Primary Children’s Hospital, UT

9. Phoenix Children’s Hospital, AZ
10. Sanford Health, SD

Three major underlying drivers behind the formation of the Cancer
Moonshot 2020 Pediatrics Consortiums are:

  1.   There is increasing recognition that cancer is an extremely
heterogeneous disease, caused by any one of a multiple number of
genetic mutations, with hundreds and even thousands of molecular
alterations presenting within each pediatric cancer patient and
therefore demands of a more personalized, precision approach. This
pediatrics consortium will lead and use next-generation precision
clinical genomic-proteomics enabling doctors and patients to get the
most comprehensive molecular diagnosis in the market today.
2. While significant progress in cancer treatment has been made, there
remains significant fragmentation across the healthcare ecosystem,
with pharmaceutical drug development occurring in silos with limited
ability to share clinical information efficiently, especially
cutting-edge immunotherapy treatment options and patient outcomes to
guide in treatment decisions. Consortium participants have
recognized that the collaboration among pharma, oncology and others
in the medical and scientific community, combined with leading whole
genomic and proteomic sequencing analysis and the huge breadth of
immunotherapy clinical trials provided via the Cancer MoonShot 2020
program, is a much needed means to reduce the barriers to
accelerated progress in the war on pediatric cancer.
3. Cancer MoonShot 2020 provides access to a national, robust and
scaled cloud infrastructure enabling the ability to share data in
real time and to provide rapid access to breakthrough knowledge to
all. Academic institutions now have the capability to share complex
pan-omic data tied to phenotypic medical records and clinical
outcomes. Such a comprehensive system, combined with multiple pharma
participation has not been available to any of the individual
children cancer centers before on such a national basis and this
infrastructure will accelerate clinical trial and drug development,
establishing the National Pediatrics Cancer Learning System to
accelerate the next-generation of care for all.

According to the American Cancer Society, cancer is the second leading
cause of death in children (after accidents) and an estimated 10,380
children in the United States under the age of 15 will be diagnosed with
cancer in 2016.

“Cancer MoonShot 2020 is a pioneering initiative
bringing state-of-the-art molecular diagnostic technologies and
innovative treatment options to move us one step closer to a cancer-free
world,” said U.S. Senator John McCain. “Through the participation of
doctors and hospitals across our state, including the Phoenix Children’s
Hospital and a collaborative network of leading pediatric hospitals and
community-based pediatric oncologists, Arizona is setting an important
example for other states to follow.”

“Members joining the Pediatric Cancer Consortium recognize that progress
is clearly not moving fast enough and there is an urgent need to address
the unique needs of pediatric cancer patients by bringing the resources
of the Cancer MoonShot 2020 to the pediatric cancer community,” said
Robert Meyer, President and CEO, Phoenix Children’s Hospital. “These
include access to state-of-the-art, next-generation molecular profiling
capabilities, access to over 60 novel and approved therapies, along with
other invaluable expertise, focused on improving pediatric cancer care

“When Cancer MoonShot 2020 was launched in January 2016, one of the
major challenges identified was that while amazing progress is occurring
in cancer research today at pharmaceutical and biotech companies, that
work is conducted in silos, as each organization focuses on its’ own
drug development efforts,” said Dr. Soon-Shiong. “In addition, drug
choices and other treatment decisions get locked away in electronic
health records, which means too little information is shared on patient
outcomes. This fragmented approach, while still advancing cancer care,
is not the most optimal coordination efforts and the leaders joining
Cancer MoonShot 2020 believe, we as a nation, could do much better.”

“I’m proud to stand with Arizona on the front lines in the fight against
cancer,” said Governor Doug Ducey. “Our state is already home to some of
the finest universities, health care facilities and cancer research and
treatment centers in the country. Moonshot 2020 will elevate our efforts
to stay on the leading edge — developing next-generation technology and
innovative treatment options that will save lives and keep us a step
ahead in the war on cancer. I thank Dr. Soon-Shiong, and all of the
great Arizona individuals and institutions who are leading the charge.”

“Phoenix is proud to take a leading role in this effort because it is
critical that, as a nation, we do more and invest more to find cures for
cancers in children” said Mayor Greg Stanton. “Patients all over the
world will benefit from the work of ASU, NantWorks and top researchers
right here in downtown Phoenix.”

Michael M. Crow, President, Arizona State University: “The Cancer
MoonShot 2020 Program will link scientists and technological advances
across dozens of areas around a single goal: clinical treatments
individualized to the disease in a particular person,” ASU President
Michael M. Crow. “ASU and NantWorks share the belief that important
medical advances must be integrated quickly into society. That is
why ASU is proud to be partners with NantWorks and the Chan Soon-Shiong
Institute of Molecular Medicine in the development of a campus in
Phoenix where the next generation of scientists, clinical decision
specialists, integrated precision medicine engineers and medical data
analysts can be trained for both research and healthcare delivery.”

Cancer MoonShot 2020 Pediatrics Consortium Members:

H. Stacy Nicholson, MD, Phoenix Children’s Hospital: “The
Cancer MoonShot 2020 Pediatric Consortium has an enormous potential to
change how we diagnose and treat children suffering from cancer. I’m
personally excited about Phoenix Children’s leadership of this effort
through the Chan Soon-Shiong Children’s Precision Medicine Institute at
Phoenix Children’s and are honored to have led the initiative with Dr.
Soon-Shiong to establish this consortium.”

Leonard S. Sender, MD, Children’s Hospital of Orange County: “The
Pediatric Cancer MoonShot 2020 is so visionary and, at the same time,
has the capacity to disrupt the cancer healthcare industrial complex.
The cancer moonshot will attempt to cure all the numerous types of
pediatric cancers with the least toxicity by harnessing the patients’
own immune systems and using the tumors’ unique genomic mutations to
create individualized cancer vaccines. Our Center has studied the value
of whole genome sequencing for several years and have recognized the
enormous value in such a test to assist in clinical decision-making. Now
with the availability of the next evolution of molecular diagnostics
from the genome to the proteome we are excited by the acceleration of
knowledge that this system will provide and are honored to be a founding
member of such an important initiative.”

Douglas K. Graham, MD, PhD, Children’s Healthcare of Atlanta: “The
Pediatric Cancer Moonshot will give us genomic and proteomic tools to
provide deeper insight into the biology of pediatric cancers.
are also particularly excited about the potential to engage the immune
system in offering new hopes for curative therapy for patients with the
highest risk cancers.”

Stewart Goldman, MD, Ann & Robert H. Lurie Children’s Hospital of
Chicago and a member of the Executive Committee of the Robert H. Lurie
Comprehensive Cancer Center:
“We are honored and excited
to participate in the Moon Shot project,” said Stewart Goldman, MD, Head
of the Division of Hematology/Oncology/Neuro-Oncology & Stem Cell
Transplantation at Lurie Children’s. “This unprecedented collaboration
is truly an opportunity to make transformational change quickly by
developing effective immunotherapy treatments for the care and cure of
children with cancer.”

Giannoula Klement, MD, Floating Hospital for Children at Tufts
Medical Center – Tufts University School of Medicine
: “This is
the most exciting time in oncology. For the first time in many decades,
we have the tools and understanding to abandon the old paradigm of
killing cancer and develop more individualized, rational, and much less
toxic approaches.”

Linda M. McAllister-Lucas, MD, PhD, Children’s Hospital of Pittsburgh
of UPMC: 
“Less than one percent of cancers in the USA occur
in pediatric patients. And yet, the loss of years and quality of life to
pediatric cancer is huge. The Pediatric Cancer Moonshot 2020 will pour
resources into research investigating the cause, the diagnosis and the
treatment of pediatric cancers. This Moonshot will start a new era of
hope for our patients and their families, and will lead the way toward
more effective less toxic treatments, and higher quality longer lives
for children with cancer.”

Sam Milanovich, MD, Sanford Health: “The National Cancer
Moonshot presents a unique opportunity to begin to fundamentally change
the way we treat childhood cancer. Sanford Health looks forward to
working together with our pediatric oncology colleagues across the
country to develop exciting, novel approaches to improve childhood
cancer treatment.”

Joshua D. Schiffman, MD, Professor of Pediatrics and Investigator,
Huntsman Cancer Institute, University of Utah and Intermountain Primary
Children’s Hospital:
“This effort offers a unique and timely
opportunity to harness the power of genomic translation to eventually
help the nearly 16,000 children diagnosed with cancer each year in the
United States.
We are very pleased that Utah and its children can
contribute to this initiative.”

Phillip B. Storm, MD, Children’s Hospital of Philadelphia: “We
are delighted to participate in this cancer moonshot coalition. We have
been invited to lead glioblastoma and the brain tumor working group in
this coalition. We already have underway a network of pediatric cancer
centers involved in genomic and proteomics research and being part of
the Cancer MoonShot 2020 will help accelerate this goal to find

Daniel S. Wechsler, MD, PhD, Duke Department of Pediatrics – Duke
University School of Medicine:
“I am excited to learn more
about this extraordinary initiative to enhance cure rates among
pediatric cancer patients. Recent advances in immunotherapy have set the
stage for the National Immunotherapy Coalition to make tremendous

About the Cancer MoonShot 2020 Pediatrics Consortium:
Cancer MoonShot 2020 Pediatrics Consortium, founded by ten initiating
members, will bring the promise of immunotherapy as the next-generation
standard of cancer care to children diagnosed with the disease. The
consortium will seek to apply the most comprehensive diagnostic testing
available—whole genomic and proteomic analysis—and leverage proven and
promising combination immunotherapies and clinical trials under the
QUILT Program within the Cancer MoonShot 2020 mission. Real-time
outcomes data will be shared to establish a National Pediatrics Cancer
Learning System to accelerate the next generation of care for all.

About Cancer MoonShot 2020
Cancer MoonShot 2020 is the
nation’s most comprehensive cancer collaborative initiative seeking to
accelerate the potential of combination immunotherapy as the
next-generation standard of care in cancer patients. This initiative
aims to explore a new paradigm in cancer care by initiating randomized
Phase II trials in patients at all stages of disease in 20 tumor types
in 20,000 patients within the next 36 months. These findings will inform
Phase III trials and the aspirational moonshot to develop an effective
vaccine-based immunotherapy to combat cancer by 2020. For more
information, please visit


Jen Hodson,562-397-3639